KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Debt: 2017-2024

Historic Non-Current Debt for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $2.2 billion.

  • Amneal Pharmaceuticals' Non-Current Debt rose 18.29% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 18.29%. This contributed to the annual value of $2.2 billion for FY2024, which is 9.40% down from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Non-Current Debt is $2.2 billion, which was down 9.40% from $2.4 billion recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Non-Current Debt registered a high of $2.7 billion during FY2020, and its lowest value of $2.2 billion during FY2024.
  • For the 3-year period, Amneal Pharmaceuticals' Non-Current Debt averaged around $2.4 billion, with its median value being $2.4 billion (2023).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Non-Current Debt grew by 4.84% in 2020, and later fell by 9.40% in 2024.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Non-Current Debt stood at $2.7 billion in 2020, then decreased by 2.02% to $2.7 billion in 2021, then fell by 3.29% to $2.6 billion in 2022, then fell by 7.95% to $2.4 billion in 2023, then dropped by 9.40% to $2.2 billion in 2024.